Health Canada Will Review Request for Masitinib as Add-on Therapy
Health Canada has authorized a new drug submission for masitinib — AB Science’s add-on therapy for amyotrophic…
Articles by Lindsey Shapiro, PhD
FDA, Amylyx Meeting to Review AMX0035 for Possible Approval
A U.S. Food and Drug Administration (FDA) advisory committee has scheduled a virtual meeting with Amylyx Pharmaceuticals to review its…
NP001 Slows ALS Progression in Middle-aged Patients With Inflammation
NP001 slowed functional and lung declines in a subset of middle-aged patients with amyotrophic lateral…
Urine Levels of Neopterin May Help Determine Therapy Efficacy in Trials
Urine levels of neopterin, a marker of inflammation, are linked to disease progression in people with amyotrophic lateral sclerosis…
FDA Approves Phase 2 Trial of Psychedelic Ketamine in ALS
The U.S. Food and Drug Administration (FDA) has approved a Phase 2 clinical trial of the psychedelic ketamine, PharmaTher’s…